Share

In This Section

Home / Blurb / Discussion Detail

FDA Approves Lurbinectedin in Combination With Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for Extensive-stage Small Cell Lung Cancer

On October 2, the FDA approved lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs for the maintenance treatment of adult patients with extensive-stage small cell lung cancer whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin, and etoposide.

For more information, read the FDA announcement and the Jazz Pharmaceuticals press release.

Posted on 10/3/2025